Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1991-9-25
pubmed:abstractText
A series of 5'-haloalkyl-modified analogues of 5'-deoxy-5'-(methylthio)adenosine (MTA), a nucleoside byproduct of polyamine biosynthesis, has been synthesized: 5'-deoxy-5'-[(2-monofluoroethyl)thio]adenosine (10), 5'-deoxy-5'-[(2-chloroethyl)thio]adenosine (4), 5'-deoxy-5'-[(2-bromoethyl)thio] adenosine (5), and 5'-deoxy-5'-[(3-monofluoropropyl)thio]adenosine (13). On the basis of their abilities to serve as substrates of MTA phosphorylase prepared from mouse liver, several of these analogues were characterized for their growth inhibitory effects in MTA phosphorylase-containing (murine L5178Y and human MOLT-4) and MTA phosphorylase-deficient (murine L1210 and human CCRF-CEM) leukemia cell lines. The MTA phosphorylase-containing tumor cell lines, especially of human origin, were found to be more sensitive to treatment by these analogues. Of the analogue series, 10 was the most potent inhibitor of growth in each of the cell lines tested. The analogues, especially compound 10, displayed a reduced capacity to alter polyamine pools relative to MTA, mechanistically indicating a decreased potential for interactions at sites other than MTA phosphorylase. The results indicate that of the analogues tested, compound 10 displayed the best inhibitor/substrate interaction with MTA phosphorylase, which, in turn, correlated with more potent growth inhibition in tumor cell lines containing MTA phosphorylase. Overall, this supports the concept that MTA phosphorylase plays a role in the activation of such analogues.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2600-6
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:1908523-Adenosine, pubmed-meshheading:1908523-Adenosylhomocysteinase, pubmed-meshheading:1908523-Animals, pubmed-meshheading:1908523-Antineoplastic Agents, pubmed-meshheading:1908523-Cell Division, pubmed-meshheading:1908523-Chemical Phenomena, pubmed-meshheading:1908523-Chemistry, pubmed-meshheading:1908523-Deoxyadenosines, pubmed-meshheading:1908523-Drug Stability, pubmed-meshheading:1908523-Humans, pubmed-meshheading:1908523-Hydrolases, pubmed-meshheading:1908523-Leukemia, Experimental, pubmed-meshheading:1908523-Leukemia L1210, pubmed-meshheading:1908523-Liver, pubmed-meshheading:1908523-Mice, pubmed-meshheading:1908523-Molecular Structure, pubmed-meshheading:1908523-Polyamines, pubmed-meshheading:1908523-Purine-Nucleoside Phosphorylase, pubmed-meshheading:1908523-Structure-Activity Relationship, pubmed-meshheading:1908523-Thionucleosides, pubmed-meshheading:1908523-Tumor Cells, Cultured
pubmed:year
1991
pubmed:articleTitle
Targeting 5'-deoxy-5'-(methylthio)adenosine phosphorylase by 5'-haloalkyl analogues of 5'-deoxy-5'-(methylthio)adenosine.
pubmed:affiliation
Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.